B2M Knockout A375 Cell Line

The choice depends on whether you are studying B2M in melanoma context for checkpoint inhibitor resistance research. The Knockout line is the standard tool for asking whether B2M is required for these processes in BRAF V600E melanoma context — B2M loss is a documented mechanism of acquired resistance to anti-PD-1 (pembrolizumab/nivolumab) and anti-CTLA-4 (ipilimumab) in melanoma; landmark studies (Zaretsky et al. NEJM 2016; Sade-Feldman et al. Nat Commun 2017) identified B2M mutations in melanoma patients who relapsed after initial checkpoint inhibitor response. Overexpression is useful for studying B2M gain-of-function effects. For melanoma immunotherapy resistance research, the EDITGENE B2M Knockout in A-375 is uniquely valuable — A-375 is BRAF V600E-mutant melanoma, the principal melanoma model and the most clinically relevant context for B2M-mediated checkpoint inhibitor resistance. This product complements the parallel B2M Knockouts in HEK293T (biochemistry) and A-549 (lung cancer) for cross-background validation. The knockout is uniquely valuable for studying acquired checkpoint inhibitor resistance — one of the most clinically important problems in immunotherapy.

Primary applications: • Melanoma checkpoint inhibitor resistance: critical genetic model for studying ⭐⭐⭐ pembrolizumab, nivolumab, ipilimumab acquired resistance — B2M loss is the most well-characterized escape mechanism (Zaretsky et al. NEJM 2016). • BRAF/MEK inhibitor combination: in BRAF V600E melanoma context, B2M's role in vemurafenib/dabrafenib + immunotherapy combination response. • Tumor neoantigen presentation: MHC I-restricted neoantigen presentation analysis given melanoma's high tumor mutation burden. • Cross-background validation: parallel analysis with B2M KOs in HEK293T and A-549 (both available). EDITGENE recommends this BRAF V600E melanoma model as the gold-standard genetic model for studying acquired checkpoint inhibitor resistance — the most clinically important immunotherapy resistance mechanism.

Yes. B2M rescue in A-375 is gold-standard for checkpoint inhibitor resistance research: • Construct design: same considerations as B2M/HEK293T rescue. • Melanoma anti-PD-1 response: WT B2M rescue restores MHC I-restricted melanoma neoantigen presentation and pembrolizumab/nivolumab-induced tumor killing. • Acquired resistance modeling: rescue with patient-derived B2M mutations (truncation, missense) enables on-target validation of B2M-mediated checkpoint inhibitor resistance. • Functional readout: rescue should restore HLA-ABC surface expression and melanoma neoantigen-specific CD8+ T cell recognition. A-375-specific considerations: • A-375 is a human melanoma cell line with BRAF V600E mutation — the principal in vitro model for BRAF-driven melanoma biology and BRAF/MEK inhibitor research. • Lentiviral transduction is supported with moderate efficiency. • MAPK pathway-driven cancer biology is the dominant feature of A-375.